Published results of the Patriquin, et al., clinical trial of a microscopy-based test demonstrate overall 81% accuracy and confirm that TCPP is an important biomarker for lung cancer detection. This study of New Mexico military veterans at high risk for lung cancer uses cytology to identify cells labeled by TCPP indicating cancer is present. The trial builds upon an earlier study at Los Alamos National Laboratory of 12 uranium miners that resulted in 100% sensitivity and 100% specificity. 

bioAffinity Technologies and Precision Pathology Services, an established anatomical pathology laboratory serving hospitals and physicians for 18 years, begin commercialization of CyPath® Lung as a Laboratory Developed Test (LDT) accredited by the College of American Pathologists (CAP) and certified under the US Centers for Medicare and Medicaid Services (CMS) Clinical Laboratory Improvement Act (CLIA).

bioAffinity Technologies conducts successful Intial Public Offering, leading to acquistion of Precision Pathology Services in 2023.

CyPath® Lung is awarded Medicare, commercial payer, and federal reimbursement, spurring greater physician adoption. Pulmonologists at South Texas VA Medical Center and Brooke Army Medical Center publish a study in a peer-reviewed journal evaluating the potential economic impact of adding CyPath® Lung to the standard of care, resulting in significant cost savings for patients and America's healthcare system.